How many patients with Multiple Sclerosis (MS) do you have personally under your care?

Practice Type:

• Academic
• Private Practice
• Community Practice

Of your [X] MS patients, how many patients do you currently have on the following treatments:

• Ocrevus (IV):
• Ocrevus Zunovo (SubQ):
• Kesimpta:
• Briumvi:

What is your general view of Briumvi compared with Ocrevus?

How many NEW to anti-CD20 patients did you start/do you plan to start on the following? Do not include patients switching from one anti-CD20 drug to another anti-CD20 drug.

• Ocrevus (IV):
• Ocrevus Zunovo (SubQ):
• Kesimpta:
• Briumvi:

• Past 6 months (#)
• Next 6 months (#)

How many patients have switched in the past 6 months, and how many do you expect to switch in the next 6 months?

• From Ocrevus / Ocrevus Zunovo → Briumvi
• From Kesimpta → Briumvi
• From Briumvi → Ocrevus / Ocrevus Zunovo / Kesimpta

•  Past 6 months (#)
• Next 6 months (#)

Please elaborate on any specific reasons that might lead you to increase or decrease the number of patients starting on Briumvi (new or switch) in the next 6 months compared with the past 6 months? Please be as specific.

Of your patients who were on Ocrevus or Kesimpta before Briumvi coming market, please enter the percentages for the following already switched or expected to switch to Briumvi:

• Initially on Ocrevus → Already switched to Briumvi (%):
• Initially & still on Ocrevus → Expected to switch in next 2 years (%):
• Initially on Kesimpta → Already switched to Briumvi (%):
• Initially & still on Kesimpta → Expected to switch in next 2 years (%):

You mentioned that you have [X] total patients on the 4 branded ANTI-CD20 drugs today. How many patients TOTAL do you expect to have on the 4 branded ANTI-CD20 drug at the following points in time? 

• 1 year from now:
• 2 years from now:
• 5 years from now:

You mentioned that you currently have [X] patients on Briumvi. How many patients TOTAL do you expect to have ON BRIUMVI at the following points in time?

• 1 year from now:
• 2 years from now:
• 5 years from now:

How does the ease or difficulty of getting Briumvi approved by insurance compare with that for Ocrevus? Select one.

• Brimvi is much easier than Ocrevus
• Brimvi is a little easier than Ocrevus
• They are about the same
• Brimvi is a little more difficult than Ocrevus
• Brimvi is a lot more difficult than Ocrevus

What are the key studies, developments, or findings in the last year that have played the biggest role in shifting or shaping your preference between Briumvi and Ocrevus?

How broadly, if at all, do you expect to utilize Ocrevus Zunovo in your practice? Please elaborate

On average, how much total time does a patient receiving Ocrevus Zunovo spend in the office—from the time the patient’s treatment is started in the office to the time they are allowed to leave?

• Less than 30 minutes
• 30 mins–1 hour
• 1–1.5 hours
• 1.5–2 hours
• 2–3 hours
• More than 3 hours
• I don’t have enough experience to estimate
• Other, specify:

How has the availability of Ocrevus Zunovo impacted the number of patients that you expect to have on BRIUMVI by the end of 2025? Select one.

• Greatly reduced the number of Briumvi patients
• Modestly reduced the number of Briumvi patients
• Had no impact on the number of Briumvi patients
• Modestly increased the number of Briumvi patients
• Greatly increased the number of Briumvi patients